What? Antiviral drug molnupiravir (Merck & Ridgeback Biotherapeutics & we call it 'MONEY-PIRAVIR') linked to driving COVID virus mutations? see NATURE (Sanderson et al.); Molnupiravir & Paxlovid are

failed dangerous antivirals & CDC, FDA, NIH know this! Molnupiravir induces mutations in the virus's genetic information as it replicates; did the idiots at Merck not think it would cause MORE?

https://medicalxpress.com/news/2023-09-antiviral-drug-molnupiravir-linked-sars-cov-.html

‘Researchers at the Francis Crick Institute, the University of Cambridge, Imperial College London, the University of Liverpool, the University of Cape Town and UKHSA have uncovered a link between an antiviral drug for COVID-19 infections called molnupiravir and a pattern of mutations in the SARS-CoV-2 virus.’

‘These mutations increased in 2022, coinciding with the introduction of molnupiravir. They were also more likely to be seen in older age groups, consistent with the use of the antivirals to treat people who are more at risk, and in countries which are known to have high molnupiravir use. In England, the researchers analyzed treatment data and found that at least 30% of the events involved use of molnupiravir.’

https://www.nature.com/articles/s41586-023-06649-6

‘Researchers ‘show that SARS-CoV-2 sequencing databases contain extensive evidence of molnupiravir mutagenesis. Using a systematic approach, we find that a specific class of long phylogenetic branches, distinguished by a high proportion of G-to-A and C-to-T mutations, appear almost exclusively in sequences from 2022, after the introduction of molnupiravir treatment, and in countries and age-groups with widespread usage of the drug. We identify a mutational spectrum, with preferred nucleotide contexts, from viruses in patients known to have been treated with molnupiravir and show that its signature matches that seen in these long branches, in some cases with onwards transmission of molnupiravir-derived lineages. Finally, we analyse treatment records to confirm a direct association between these high G-to-A branches and the use of molnupiravir.’